REGN Jan 2026 550.000 put
| Previous close | 9.60 |
| Open | N/A |
| Bid | 5.10 |
| Ask | 15.00 |
| Strike | 550.00 |
| Expiry date | 2026-01-16 |
| Day's range | 9.60 - 9.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Simply Wall St.Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock...
Investor's Business DailyRegeneron Earnings Miss; Biotech Giant's Stock Falls
Regeneron Pharmaceuticals earnings and sales missed first-quarter estimates early Thursday. Shares fell slightly.
- Reuters
UPDATE 3-Regeneron's blockbuster eye drug posts weaker sales due to inventory impact
U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall Street estimates for quarterly profit on Thursday, hurt by softer sales of its blockbuster eye drug Eylea due to reduction in wholesaler inventory. Apart from an impact of about $40 million cut in inventory, Regeneron said changing market dynamics that resulted in lower volumes and lower selling price also hurt Eylea sales. Total sales of the drug, jointly developed with Bayer AG , fell 2% to $1.40 billion in the January-to-March quarter, missing estimates of $1.86 billion, according to LSEG estimates.
